more

Pacira BioSciences (PCRX)

(Real Time Quote from BATS)

$15.29 USD

-0.01 (-0.07%)

Updated Oct 2, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

Top 37% (93 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research Published on August 04,2021

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Pacira (PCRX) Q2 Earnings Surpass Estimates

by Zacks Equity Research Published on August 03,2021

Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PCRXNegative Net Change

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on July 27,2021

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PCRXNegative Net Change

Moving Average Crossover Alert: Pacira BioSciences (PCRX)

by Zacks Equity Research Published on June 15,2021

Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

PCRXNegative Net Change

medical

How Has PCRX Performed 30 Days Post Earnings

by Zacks Equity Research Published on June 03,2021

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRXNegative Net Change

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research Published on May 05,2021

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research Published on May 05,2021

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales

by Zacks Equity Research Published on May 05,2021

Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research Published on May 05,2021

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Pacira (PCRX) Q1 Earnings Lag Estimates

by Zacks Equity Research Published on May 04,2021

Pacira (PCRX) delivered earnings and revenue surprises of -10.17% and 1.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

PCRXNegative Net Change

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 27,2021

Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.

Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?

by Zacks Equity Research Published on April 27,2021

Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 27,2021

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

Centene (CNC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 23,2021

Centene's (CNC) first-quarter results are likely to reflect improving premiums and rise in membership, partly offset by escalating costs.

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research Published on April 23,2021

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

pharmaceuticals

Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on March 27,2021

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRXNegative Net Change

Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

by Zacks Equity Research Published on March 23,2021

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

medical

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research Published on February 26,2021

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

Pacira (PCRX) Q4 Earnings Beat Estimates

by Zacks Equity Research Published on February 25,2021

Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PCRXNegative Net Change

AMRX or PCRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on January 15,2021

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Pacira (PCRX) Gets European Commission Approval for Exparel

by Zacks Equity Research Published on November 19,2020

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

pharmaceuticals

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research Published on October 30,2020

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

medical

Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on October 29,2020

Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PCRXNegative Net Change

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on October 22,2020

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PCRXNegative Net Change